Cargando…

Rapid generation and selection of Cas9-engineering TRP53 R172P mice that do not have off-target effects

BACKGROUND: Genetic mutations cause severe human diseases, and suitable animal models to study the regulatory mechanisms involved are required. The CRISPR/Cas9 system is a powerful, highly efficient and easily manipulated tool for genetic modifications. However, utilization of CRISPR/Cas9 to introdu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Guoxing, Zhu, Qingqing, Dong, Junchao, Lin, Xin, Zhu, Chengming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839086/ https://www.ncbi.nlm.nih.gov/pubmed/31703569 http://dx.doi.org/10.1186/s12896-019-0573-z

Ejemplares similares

The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/–) and Trp53(−/−) mice
por: Krais, Annette M., et al.
Publicado: (2015)

Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
por: Zhang, Xiao-Hui, et al.
Publicado: (2015)

Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity
por: van der Weyden, L, et al.
Publicado: (2013)

Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?
por: Blackburn, Anneke C, et al.
Publicado: (2002)

Are Trp53 rescue of Brca1 embryonic lethality and Trp53/Brca1 breast cancer association related?
por: McAllister, Kimberly A, et al.
Publicado: (2002)

The Trp53-Trp53inp1-Tnfrsf10b Pathway Regulates the Radiation Response of Mouse Spermatogonial Stem Cells
por: Ishii, Kei, et al.
Publicado: (2014)

Rapid poxvirus engineering using CRISPR/Cas9 as a selection tool
por: Gowripalan, Anjali, et al.
Publicado: (2020)

Improved CRISPR/Cas9 Tools for the Rapid Metabolic Engineering of Clostridium acetobutylicum
por: Wilding-Steele, Tom, et al.
Publicado: (2021)

p53 Regulation by TRP2 Is Not Pervasive in Melanoma
por: Houben, Roland, et al.
Publicado: (2014)

SMOOT libraries and phage-induced directed evolution of Cas9 to engineer reduced off-target activity
por: Cerchione, Derek, et al.
Publicado: (2020)

CRISPRon/off: CRISPR/Cas9 on- and off-target gRNA design
por: Anthon, Christian, et al.
Publicado: (2022)

Genetic variation may confound analysis of CRISPR-Cas9 off-target mutations
por: Wang, Guanqun, et al.
Publicado: (2018)

Effect of cryopreservation on A172 and U251 glioma cells infected with lentiviral vectors designed for CRISPR/Cas9-mediated aquaporin-8 knock-out
por: Zhang, Hao, et al.
Publicado: (2022)

Maintenance of pluripotency in mouse ES cells without Trp53
por: Shigeta, Masaki, et al.
Publicado: (2013)

Differential Effects of Trp53 Alterations in Murine Colorectal Cancer
por: Betzler, Alexander M., et al.
Publicado: (2021)

Distinct oncogenic phenotypes in hematopoietic specific deletions of Trp53
por: Palanichamy, Jayanth Kumar, et al.
Publicado: (2023)

CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity
por: Cradick, Thomas J., et al.
Publicado: (2013)

Off-target effects in CRISPR/Cas9 gene editing
por: Guo, Congting, et al.
Publicado: (2023)

Chemosensitivity to doxorubicin in primary cells derived from tumor of FVB/N-Trp53(tm1Hw1) with TALEN-mediated Trp53 mutant gene
por: Yun, Woobin, et al.
Publicado: (2023)

LSL-Kras(G12D); LSL-Trp53(R172H/+); Ink4(flox/+); Ptf1/p48-Cre mice are an applicable model for locally invasive and metastatic pancreatic cancer
por: Ma, Lixiang, et al.
Publicado: (2017)

CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences
por: Lin, Yanni, et al.
Publicado: (2014)

Engineered CRISPR/Cas9 enzymes improve discrimination by slowing DNA cleavage to allow release of off-target DNA
por: Liu, Mu-Sen, et al.
Publicado: (2020)

Genome‐wide off‐target analyses of CRISPR/Cas9‐mediated T‐cell receptor engineering in primary human T cells
por: Kaeuferle, Theresa, et al.
Publicado: (2022)

Cas9 activates the p53 pathway and selects for p53-inactivating mutations
por: Enache, Oana M., et al.
Publicado: (2020)

Chemoprevention with the metabolism modifying drugs dichloroacetate and metformin in Trp53+/- mice
por: Blackburn, AC, et al.
Publicado: (2012)

Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes
por: Haley, Victoria L, et al.
Publicado: (2012)

Nucks1 synergizes with Trp53 to promote radiation lymphomagenesis in mice
por: Yue, Yangbo, et al.
Publicado: (2016)

Chromosome engineering in zygotes with CRISPR/Cas9
por: Boroviak, Katharina, et al.
Publicado: (2016)

Loss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice
por: Branca, Jane A, et al.
Publicado: (2020)

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy
por: Gao, Qianqian, et al.
Publicado: (2019)

CRISPR–Cas9-based genetic engineering for crop improvement under drought stress
por: Sami, Abdul, et al.
Publicado: (2021)

Dual sgRNA-directed gene knockout using CRISPR/Cas9 technology in Caenorhabditis elegans
por: Chen, Xiangyang, et al.
Publicado: (2014)

Variable expressivity of the tumour suppressor protein TRP53 in cryopreserved human blastocysts
por: Chandrakanthan, Vashe, et al.
Publicado: (2007)

Role of JNK in a Trp53-Dependent Mouse Model of Breast Cancer
por: Cellurale, Cristina, et al.
Publicado: (2010)

Brca2 and Trp53 Deficiency Cooperate in the Progression of Mouse Prostate Tumourigenesis
por: Francis, Jeffrey C., et al.
Publicado: (2010)

Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice
por: Albers, Joachim, et al.
Publicado: (2013)

Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6-deficient mice
por: Ghosh, Shrestha, et al.
Publicado: (2018)

Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases
por: Zhang, Yun, et al.
Publicado: (2018)

RINT1 Loss Impairs Retinogenesis Through TRP53-Mediated Apoptosis
por: Gomes, Anielle L., et al.
Publicado: (2020)

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
por: Mirgayazova, Regina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ng7h3p920maiitv0gmfas2826a